Skip To Content

Study ID: Medimmune AZ D5290C00003 Prevention of RSV in Infants

Title:

A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Location:
Sioux Falls Region
Principal Investigator:
Archana Chatterjee, MD, PhD
Disease:
Lung
Stage:
N/A
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.